ICON Management
Management criteria checks 4/4
ICON's CEO is Steve Cutler, appointed in Mar 2017, has a tenure of 7.17 years. total yearly compensation is $10.03M, comprised of 11.6% salary and 88.4% bonuses, including company stock and options. directly owns 0.045% of the company’s shares, worth $11.19M. The average tenure of the management team and the board of directors is 12.3 years and 7.1 years respectively.
Key information
Steve Cutler
Chief executive officer
US$10.0m
Total compensation
| CEO salary percentage | 11.6% |
| CEO tenure | 7.2yrs |
| CEO ownership | 0.04% |
| Management average tenure | 12.3yrs |
| Board average tenure | 7.1yrs |
Recent management updates
Recent updates
ICON Public Limited Company Just Recorded A 8.9% EPS Beat: Here's What Analysts Are Forecasting Next
Apr 28
What Does ICON Public Limited Company's (NASDAQ:ICLR) Share Price Indicate?
Apr 21ICON Public Limited Company's (NASDAQ:ICLR) Intrinsic Value Is Potentially 33% Above Its Share Price
Apr 05ICON Public Limited Company (NASDAQ:ICLR) Looks Just Right With A 27% Price Jump
Mar 05With EPS Growth And More, ICON (NASDAQ:ICLR) Makes An Interesting Case
Feb 07ICON: Will The Huge Acquisition Of PRA Continue To Create Synergies?
Feb 01These 4 Measures Indicate That ICON (NASDAQ:ICLR) Is Using Debt Reasonably Well
Jan 23Is It Too Late To Consider Buying ICON Public Limited Company (NASDAQ:ICLR)?
Jan 08What You Can Learn From ICON Public Limited Company's (NASDAQ:ICLR) P/E
Dec 24A Look At The Fair Value Of ICON Public Limited Company (NASDAQ:ICLR)
Dec 09With EPS Growth And More, ICON (NASDAQ:ICLR) Makes An Interesting Case
Nov 08Why ICON Public Limited Company (NASDAQ:ICLR) Could Be Worth Watching
Oct 09Is ICON (NASDAQ:ICLR) Using Too Much Debt?
Sep 23Calculating The Fair Value Of ICON Public Limited Company (NASDAQ:ICLR)
Sep 05Does ICON (NASDAQ:ICLR) Deserve A Spot On Your Watchlist?
Aug 03Is It Too Late To Consider Buying ICON Public Limited Company (NASDAQ:ICLR)?
Jun 30Is ICON (NASDAQ:ICLR) Using Too Much Debt?
Jun 12Calculating The Fair Value Of ICON Public Limited Company (NASDAQ:ICLR)
May 23Should You Think About Buying ICON Public Limited Company (NASDAQ:ICLR) Now?
Mar 29Is ICON (NASDAQ:ICLR) Using Too Much Debt?
Mar 11Are Investors Undervaluing ICON Public Limited Company (NASDAQ:ICLR) By 28%?
Feb 21Why ICON Public Limited Company (NASDAQ:ICLR) Could Be Worth Watching
Dec 28These 4 Measures Indicate That ICON (NASDAQ:ICLR) Is Using Debt Reasonably Well
Dec 10Is ICON Public Limited Company (NASDAQ:ICLR) Trading At A 26% Discount?
Nov 22Icon selected by BARDA to conduct anthrax vaccine clinical trial
Oct 06Is ICON Public Limited Company (NASDAQ:ICLR) Potentially Undervalued?
Sep 15ICON (NASDAQ:ICLR) Seems To Use Debt Quite Sensibly
Aug 26Baron Funds - ICON Plc: Positioned For An Extended Period Of Revenue And Earnings Growth
Aug 11Are Investors Undervaluing ICON Public Limited Company (NASDAQ:ICLR) By 41%?
Aug 01Icon Q2 2022 Earnings Preview
Jul 26ICON (NASDAQ:ICLR) Has A Pretty Healthy Balance Sheet
May 11ICON Public Limited Company (NASDAQ:ICLR) Shares Could Be 30% Below Their Intrinsic Value Estimate
Apr 20Is There Now An Opportunity In ICON Public Limited Company (NASDAQ:ICLR)?
Feb 16We Think ICON (NASDAQ:ICLR) Can Stay On Top Of Its Debt
Jan 26Estimating The Intrinsic Value Of ICON Public Limited Company (NASDAQ:ICLR)
Jan 05Is There Now An Opportunity In ICON Public Limited Company (NASDAQ:ICLR)?
Oct 31ICON (NASDAQ:ICLR) Has A Rock Solid Balance Sheet
Oct 16Estimating The Fair Value Of ICON Public Limited Company (NASDAQ:ICLR)
Oct 01ICON PLC: An Easy Stock To Choose For Diversified Exposure To Healthcare And Clinical Research
Aug 26CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | US$683m |
| Dec 31 2023 | n/a | n/a | US$612m |
| Sep 30 2023 | n/a | n/a | US$513m |
| Jun 30 2023 | n/a | n/a | US$510m |
| Mar 31 2023 | n/a | n/a | US$510m |
| Dec 31 2022 | US$10m | US$1m | US$505m |
| Sep 30 2022 | n/a | n/a | US$464m |
| Jun 30 2022 | n/a | n/a | US$210m |
| Mar 31 2022 | n/a | n/a | US$168m |
| Dec 31 2021 | US$10m | US$1m | US$153m |
| Sep 30 2021 | n/a | n/a | US$178m |
| Jun 30 2021 | n/a | n/a | US$364m |
| Mar 31 2021 | n/a | n/a | US$338m |
| Dec 31 2020 | US$8m | US$1m | US$328m |
| Sep 30 2020 | n/a | n/a | US$322m |
| Jun 30 2020 | n/a | n/a | US$324m |
| Mar 31 2020 | n/a | n/a | US$368m |
| Dec 31 2019 | US$8m | US$1m | US$369m |
| Sep 30 2019 | n/a | n/a | US$362m |
| Jun 30 2019 | n/a | n/a | US$353m |
| Mar 31 2019 | n/a | n/a | US$333m |
| Dec 31 2018 | US$8m | US$1m | US$323m |
| Sep 30 2018 | n/a | n/a | US$306m |
| Jun 30 2018 | n/a | n/a | US$295m |
| Mar 31 2018 | n/a | n/a | US$288m |
| Dec 31 2017 | US$7m | US$1m | US$281m |
Compensation vs Market: Steve's total compensation ($USD10.03M) is about average for companies of similar size in the US market ($USD13.56M).
Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.
CEO
Steve Cutler (63 yo)
7.2yrs
Tenure
US$10,028,000
Compensation
Dr. Steven A. Cutler, also known as Steve, Ph D., MBA, serves as Chairman of Association of Clinical Research Organizations since January 01, 2021. He has been the Chief Executive Officer of ICON Public Li...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Independent Non-Executive Director | no data | US$290.00k | 0.54% $ 135.7m | |
| Chief Financial Officer | 12.3yrs | US$2.06m | 0.027% $ 6.7m | |
| CEO & Director | 7.2yrs | US$10.03m | 0.045% $ 11.2m | |
| Senior Vice President of Corporate & Commercial Finance | no data | no data | no data | |
| Chief Information Officer | no data | no data | no data | |
| Chief Administrative Officer | 14.5yrs | no data | no data | |
| Director of Corporate Communications | no data | no data | no data | |
| Vice President of Marketing | no data | no data | no data | |
| Chief Human Resources Officer | 7.8yrs | no data | no data | |
| President of Corporate Investments & Partnerships | 1.5yrs | no data | no data | |
| Senior Vice President of Global Clinical Pharmacology | 15.1yrs | no data | no data | |
| Senior Vice President of Drug Development Services - CNS | 17.3yrs | no data | no data |
12.3yrs
Average Tenure
52yo
Average Age
Experienced Management: ICLR's management team is seasoned and experienced (12.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Independent Non-Executive Director | 14.3yrs | US$290.00k | 0.54% $ 135.7m | |
| CEO & Director | 8.5yrs | US$10.03m | 0.045% $ 11.2m | |
| Independent Director | 2.8yrs | US$231.00k | 0.0054% $ 1.3m | |
| Independent Non-Executive Director | 6.6yrs | US$323.00k | 0.0026% $ 640.9k | |
| Independent Non-Executive Chairman of the Board | 12.6yrs | US$630.00k | 0.023% $ 5.8m | |
| Lead Independent Director | 7.6yrs | US$359.00k | 0.0026% $ 640.9k | |
| Independent Non-Executive Director | 6.5yrs | US$323.00k | 0.0026% $ 640.9k | |
| Independent Non-Executive Director | 4.8yrs | US$310.00k | 0.0023% $ 583.6k |
7.1yrs
Average Tenure
63.5yo
Average Age
Experienced Board: ICLR's board of directors are considered experienced (7.1 years average tenure).